NASDAQ:GNLX - Nasdaq - US36870H1032 - Common Stock - Currency: USD
2.85
+0.53 (+22.84%)
The current stock price of GNLX is 2.85 USD. In the past month the price increased by 23.38%. In the past year, price decreased by -25.59%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.07 | 328.29B | ||
AMGN | AMGEN INC | 13.1 | 146.27B | ||
GILD | GILEAD SCIENCES INC | 12.68 | 122.21B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 110.44B | ||
REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.13B | ||
ARGX | ARGENX SE - ADR | 299.54 | 34.75B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.61B | ||
ONC | BEIGENE LTD-ADR | 5.88 | 25.43B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.78B | ||
NTRA | NATERA INC | N/A | 22.10B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.31B | ||
BIIB | BIOGEN INC | 7.48 | 17.35B |
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
GENELUX CORP
2625 Townsgate Road, Suite 230
Westlake Village CALIFORNIA US
Employees: 24
Phone: 18052679889
The current stock price of GNLX is 2.85 USD. The price increased by 22.84% in the last trading session.
The exchange symbol of GENELUX CORP is GNLX and it is listed on the Nasdaq exchange.
GNLX stock is listed on the Nasdaq exchange.
11 analysts have analysed GNLX and the average price target is 18.36 USD. This implies a price increase of 544.21% is expected in the next year compared to the current price of 2.85. Check the GENELUX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GENELUX CORP (GNLX) has a market capitalization of 107.53M USD. This makes GNLX a Micro Cap stock.
GENELUX CORP (GNLX) currently has 24 employees.
GENELUX CORP (GNLX) has a support level at 2.65 and a resistance level at 3.06. Check the full technical report for a detailed analysis of GNLX support and resistance levels.
The Revenue of GENELUX CORP (GNLX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the GNLX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GNLX does not pay a dividend.
GENELUX CORP (GNLX) will report earnings on 2025-05-08, before the market open.
GENELUX CORP (GNLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).
The outstanding short interest for GENELUX CORP (GNLX) is 6.96% of its float. Check the ownership tab for more information on the GNLX short interest.
ChartMill assigns a technical rating of 1 / 10 to GNLX. When comparing the yearly performance of all stocks, GNLX is a bad performer in the overall market: 84.88% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to GNLX. While GNLX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months GNLX reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 20.66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -86.04% | ||
ROE | -113.68% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to GNLX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -8.11% and a revenue growth -100% for GNLX